Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter ...

AstraZeneca and Daiichi Sankyo are evaluating datopotamab deruxtecan alone and with Tagrisso (osimertinib) as treatment for patients with advanced or metastatic EGFR-mutated nonsquamous NSCLC in the ...

ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIB. The additi ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso ...

Tango Therapeutics (TNGX) announced an update on its PRMT5 program. Based on data from the dose escalation and early dose expansion cohorts of ...